Novartis drug shows cancer promise
June 5, 2013Research and Development, Sales and Marketing ASCO, Cancer, Novartis
A Novartis drug which has been given breakthrough therapy designation by the FDA has demonstrated early promise in patients with …
Celgene predicts trio of blockbusters
June 5, 2013Sales and Marketing Celgene, Pomalidomide, Revlamid, Velcade
Europe’s medicines committee the CHMP has just adopted a positive opinion for Celgene’s new multiple myeloma treatment Pomalidomide Celgene (pomalidomide). …
HAVAS LYNX makes several leadership changes
June 5, 2013Medical Communications, Sales and Marketing Creative Lynx, HAVAS LYNX, PM Society Digital Awards
Comms agency HAVAS LYNX has realigned its senior team making a number of changes for the global firm as it …
GSK licences RA drug
June 5, 2013Research and Development, Sales and Marketing GSK, RA, morphosys
GlaxoSmithKline is gambling millions of euros on an investigational drug in a bid to get an edge in the fight …
AstraZeneca abandons late-stage RA drug
June 5, 2013Research and Development, Sales and Marketing AstraZeneca, RA, Rigel
AstraZeneca is to exit development of a new rheumatoid arthritis drug, after Phase III trials produced disappointing results.The Anglo-Swedish firm …
AstraZeneca/BMS drug granted speedy FDA review
June 5, 2013Sales and Marketing AstraZeneca, BMS, lipodystrophy
AstraZeneca and partner Bristol-Myers Squibb have been granted a priority review for their rare disease drug metreleptin. The medicine is …
Sanofi admits $285m failure
June 4, 2013Research and Development, Sales and Marketing Sanofi, its benzamide iniparib, otamixaban
Sanofi has consigned two investigational drugs to the corporate dustbin, preferring a $285 million dent in its coffers to continuing …
USP delays guidance on elemental impurities
June 4, 2013Manufacturing and Production Q3D, USP
The US Pharmacopeial Convention (USP) has agreed to postpone the deadline for implementing two new chapters on elemental impurities in …
NSCLC lift for Boehringer
June 4, 2013Research and Development, Sales and Marketing Boehringer, NSCLC
Boehringer’s pipeline has been boosted with the news that its investigational oral triple angiokinase inhibitor nintedanib plus chemotherapy, extends the …
Boehringer and Lilly launch diabetes game
June 4, 2013Medical Communications Boehringer Ingelheim, combat, lilly
Boehringer Ingelheim and Eli Lilly have launched an educational digital game for type 2 diabetes called Complications Combat. The game …
Vocera appoints president and chief executive
June 4, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Brent Lang, Vocera
Healthcare comms firm Vocera Communications has announced Brent Lang’s appointment as president and chief executive officer to the firm and …
UK government cautious on trial transparency
June 4, 2013Research and Development, Sales and Marketing Goldacre, UK, alltrials, transparency
Two ministers with responsibility for life sciences in the UK struck a cautious note over clinical trial transparency at an …
SHL attends the 2013 Japan PDA
June 4, 2013Manufacturing and Production auto injectors, autoinjector, autoinjectors, japan pda. shl pda
SHL once again had the honor of being invited to participate and speak at the PDA Japan 2013 (日本PDA製薬å¦ä¼š), which …
Promising signs for Novartis’ lung cancer drug
June 4, 2013Sales and Marketing ALK+, ASCO, LDK378, NSCLC, Novartis
Targeted lung cancer treatment LDK378 has been shown to help patients with the ALK+ gene mutation in a phase I trial.Novartis’ drug …
FDA issues draft guidance on contract manufacturing
June 3, 2013Manufacturing and Production FDA, GMP, Taylor
The US Food and Drug Administration FDA has published draft guidance on quality agreements between pharma companies and contract manufacturers. …
Sinovac appoints chief financial officer
June 3, 2013Manufacturing and Production, Research and Development, Sales and Marketing China, Sinovac
China-based biopharma products provider Sinovac Biotech has appointed vice president Nan Wang to be its chief financial officer. Previous CFO …
Europe votes yes on greater trial transparency
June 3, 2013Research and Development, Sales and Marketing Europe, Goldacre, alltrials, transparency
Europe has taken one step closer to increasing clinical trial transparency on the continent after MEPs voted yes on new …
Lilly and Roche back US research institute
May 31, 2013Research and Development, Sales and Marketing Roche, lilly, notre dame, research
Eli Lilly and Roche Diagnostics are among the key backers of a $360 million US life sciences research facility which …
NICE green light for Eylea
May 31, 2013Sales and Marketing Bayer, NICE, Regeneron
NICE has recommended Bayer’s injection Eylea as a treatment for neovascular (wet) age-related macular degeneration (AMD) if the manufacturer offers …
Fatality as blast rocks Teva manufacturing plant
May 31, 2013Manufacturing and Production Teva
One man died and more than 30 other people were injured after an explosion hit a manufacturing facility operated by …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
